Relay Therapeutics announced its Q1 2026 financial results and key updates, including FDA granting Breakthrough Therapy designation to its drug zovegalisib for PIK3CA-mutant advanced breast cancer. The company reported promising clinical data showing an 11.1-month median progression-free survival in heavily pre-treated breast cancer patients and plans to start a Phase 3 frontline trial in early 2027. Relay also initiated a Phase 1/2 trial for RLY-8161 targeting NRAS-mutant tumors and expects initial vascular anomalies data in May 2026. With $642 million in cash, the company is well-funded to continue its clinical programs through 2029.
Silvaco and NVIDIA have teamed up to enhance semiconductor design and manufacturing by integrating NVIDIA's AI and accelerated computing with Silvaco's physics-based simulation technology. This collaboration aims to create high-fidelity digital twins...
Dr. Dajun Yang, Chairman and CEO of Ascentage Pharma, was ranked No. 3 on The Medicine Maker Power List 2026 in the Small Molecules category, recognizing his leadership in oncology drug development. Under his guidance, Ascentage Pharma has advanced i...
California Water Service Group, a reliable dividend grower with 58 consecutive annual increases, has seen its stock outperform peers this year. However, rising interest rates and a shrinking yield spread versus treasuries have made it less attractive...
Silvaco has teamed up with NVIDIA to enhance semiconductor design and manufacturing through AI-powered digital twins and accelerated computing. This collaboration integrates Silvaco's physics-based simulations with NVIDIA's AI and GPU technologies to...
NVIDIA has enhanced its Agent Toolkit by integrating re-architected PhysicsNeMo libraries and updated CUDA-X libraries, enabling developers to build autonomous AI engineers with advanced physics, simulation, and quantum chemistry capabilities. This e...
